Medincell's Stock Falls 21.5% Over the Week Despite Regulatory Progress
Medincell's stock has seen a significant decline of 21.5% over the past week, closing at 22.56 euros on Friday. This drop occurs in a context of high volatility, while the biotechnology company specializing in extended-release injectable formulations shows a contrasting performance with a three-month decline of 38.06%, but still posts a positive annual increase of 40.82%.
Regulatory Milestone Announced for Olanzapine LAI
Medincell announced on Wednesday, through its partner Teva Pharmaceuticals, that the filing for marketing authorization for olanzapine LAI in Europe is scheduled for the second quarter of 2026. This extended-release injectable formulation, intended for the treatment of schizophrenia, is one of the major assets in the Montpellier-based biotech's portfolio. This announcement is part of Medincell's geographic expansion strategy, aiming to enter European regulated markets after making progress in the United States. Utilizing Teva, a leading laboratory in generics and biosimilars, ensures the French company access to the necessary commercial infrastructure for rapid market introduction once approval is obtained. This regulatory timeline represents an expected operational milestone to validate the commercial potential of Medincell’s proprietary technology based on biodegradable polymers.
Investment Bank Adjusts Medincell's Price Target
On January 29, the investment bank Stifel revised its price target on Medincell, lowering it from 37 to 33 euros, while maintaining a 'accumulate' recommendation. This 10.8% adjustment reflects increased caution from analysts due to recent volatility, but still maintains a favorable outlook with a potential upside of 46% compared to the weekly closing price. However, this adjustment in expectations does not fully explain the extent of the observed stock decline. From a technical standpoint, the stock is now trading below its 20-day (26.23 euros) and 50-day (26.55 euros) moving averages, indicating persistent selling pressure. The RSI at 38 suggests approaching oversold territory, though not yet reaching critical levels. The monthly volatility at 22.78% reflects the uncertainty surrounding the stock, while the support identified at 15.63 euros represents a major psychological threshold in case of further declines. The resistance at 38.46 euros remains a distant target in the current unfavorable market environment for the biotechnology sector.
